163848-46-2

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Difluorophenetole is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents. Its unique properties make it a valuable component in the production process, enhancing the efficacy and functionality of the final drug products.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-Difluorophenetole serves as an intermediate in the production of various agrochemicals, including pesticides and herbicides. Its role in these applications helps to improve crop protection and yield, ensuring food security and agricultural productivity.
Used as a Solvent:
3,4-Difluorophenetole can be utilized as a solvent in various chemical processes, providing a medium for reactions to occur. Its solvent properties may be beneficial in situations where specific reaction conditions are required, or where other solvents may not be suitable.
Used in Organic Synthesis:
As a building block in organic synthesis, 3,4-Difluorophenetole is employed in the creation of complex organic molecules. Its structural features make it a useful component in the synthesis of a wide range of organic compounds, from pharmaceuticals to specialty chemicals.

InChI:InChI=1/C8H8F2O/c1-2-11-6-3-4-7(9)8(10)5-6/h3-5H,2H2,1H3

Upstream product

• 2713-33-9 3,4-difluorophenol 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 

Downstream Products

• 167684-02-8 6-ethoxy-2,3-difluoro-benzaldehyde 
• 181305-40-8 1-(5-Bromo-pyridin-2-yl)-3-[2-(6-ethoxy-2,3-difluoro-phenyl)-ethyl]-thiourea 
• 1026343-70-3 1-Ethoxy-3,4-difluoro-2-((E)-2-nitro-vinyl)-benzene 
• 1027179-28-7 2,3-difluoro-6-ethoxyphenethylamine 
• 1610035-34-1 1-(5-ethoxy-2-fluorophenyl)piperidin-4-ol 
• 1610035-67-0 2-((1-(5-ethoxy-2-fluorophenyl)piperidin-4-yl)oxy)-5-iodopyridine 

Relevant academic research and scientific papers

A 1- alkoxyl fluorinegeneration of benzene apperception composition preparation method

The invention relates to a preparation method for a 1-(alkoxy)fluorobenzene compound. The method includes the steps of making fluorophenol and inorganic bases react to generate base metal salt of fluorophenol; secondly, dropwise adding haloalkane to generate 1-(alkoxy)fluorobenzene and salt. The method is simple in process and convenient to operate, the obtained product is high in purity, yield is high, the environment pollution is small, and the method is suitable for large-scale industrial production.

SPIROINDOLINONE DERIVATIVES

The present invention relates to spiroindolinone derivatives of the formula and their enantiomers and pharmaceutically acceptable salts and esters thereof wherein R1, R2, R3, R4, R5, R6, R7 and R8, are as herein described.

N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection

A method for treating HIV which comprises a compound of the formula STR1 wherein A is STR2 and Zi is O, Se, NRa or C(Ra)2, and Zii is --O or (=O)2 ; wherein R1, R2, R3, and R4 are as defined in the specification.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.